Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism.

Authors :: Bellini E
Pia A
Brizzi MP
Tampellini M
Torta M
Terzolo M
Dogliotti L
Berruti A
Source :: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2011 Apr; Vol. 22 (4), pp. 988-990. Date of Electronic Publication: 2011 Feb 14.
Publication Year :: 2011

Subjects :: Antineoplastic Agents therapeutic use
Benzenesulfonates therapeutic use
Fibroblast Growth Factor-23
Humans
Kidney Neoplasms drug therapy
Male
Middle Aged
Niacinamide analogs & derivatives
Phenylurea Compounds
Pyridines therapeutic use
Sorafenib
Antineoplastic Agents adverse effects
Benzenesulfonates adverse effects
Fibroblast Growth Factors metabolism
Hypophosphatemia chemically induced
Hypophosphatemia metabolism
Pyridines adverse effects

Language :: English
ISSN :: 1569-8041
Volume :: 22
Issue :: 4
Database :: MEDLINE
Journal :: Annals of oncology : official journal of the European Society for Medical Oncology
Publication Type :: Report
Accession number :: 21321087
Full Text :: https://doi.org/10.1093/annonc/mdr010

Full Text Access

Tools